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Background: Idiopathic pulmonary ﬁbrosis (IPF) is a progressive interstitial lung disease with a
poor prognosis. Recently, pirfenidone was reported to slow the rate of decline in vital capacity
and improve progression-free survival in IPF. The purpose of this study was to clarify the
factors that predicted a good response to pirfenidone, as well as its adverse effects.
Methods: Forty-one IPF cases, treated with pirfenidone from January 2009 to January 2011,
were enrolled in this investigation. Disease severity was classiﬁed into grades I–IV, as deﬁned
by the Japanese Respiratory Society (JRS). Short-term responsiveness to pirfenidone was
evaluated by the modiﬁed criteria of the JRS. Predictors of nausea, anorexia, or both that
represented important adverse effects were examined by multivariate Cox proportionalSociety. Published by Elsevier B.V.
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Acid-secretion inhibitorshazard analyses. Predictors of short-time responsiveness were examined by multivariate
logistic regression analyses.
Results: Diagnosed by a surgical lung biopsy (SLB), the mild cases of grade I/II were predictors
of good, short-term responsiveness. Patients taking acid-secretion inhibitors, including proton
pump inhibitors and histamine H2-receptor antagonists, showed less anorexia, nausea, or
both. Only 1 case was administered drugs to activate gastrointestinal motility.
Conclusions: We concluded that IPF patients with a mild disease, diagnosis by SLB, or both
showed indications of a good response to pirfenidone. In addition, acid-secretion inhibitors
may reduce the frequency of anorexia, nausea, or both from pirfenidone.
& 2013 The Japanese Respiratory Society. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.Table 1 – Patient demographics at the commencement
of pirfenidone.
Parameters Frequency or median (IQR)
Total (n) 41 cases
Gender, male (n)/female (n) 34/7
Age, (years) 70 (65.5–75.5)
Smoking status (n), CS/ES/NS 6/24/11
Diagnosis (n), Clinical/SLB 23/18
Modiﬁed MRC scale (n),
grade 0/1/2/3/4
2/6/18/12/3
VC, %predicted (%) 66.7 (54.8–77.8)
Severity grade of IPF (n), I/II/III/IV 9/5/9/18
Serum KL-6 (U/mL) 858 (1600687)
Serum SP-D (ng/mL) 187 (138–299)
Serum cholinesterase (U/L) 270 (216–327)
Long term oxygen therapy (n),
Yes/No
22/19
Treatment before pirfenidone
Corticosteroid alone (n) 3
Corticosteroid and
azathioprine (n)
4
Corticosteroid and 11. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a lung disease with a
poor prognosis that includes the progressive deterioration of
pulmonary function. Its etiology is unknown, and there is no
proven effective therapy [1,2]. The pathophysiology of IPF is
not fully understood; however, treatments targeting the
ﬁbrotic pathway and epithelial injury are supposed to attenu-
ate IPF progression [3].
Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) elicits
both antiﬁbrotic and anti-inﬂammatory effects in experimen-
tal pulmonary ﬁbrosis models [4]. Open-label studies have
revealed that pirfenidone stabilizes IPF disease progression
[5,6]. A phase III clinical trial conducted in Japan showed that
vital capacity (VC) declined to a lesser degree in pirfenidone-
treated IPF patients than that of placebo-treated patients [7].
A signiﬁcant difference in the progression-free survival was
also observed between the 2 groups. On the basis of these
ﬁndings, in 2008, pirfenidone was approved for IPF treatment
in Japan. However, Noble et al. reported controversial results
from 2 concurrent phase III trials in the United States [8].
The adverse effects of pirfenidone have been frequently
observed. A phase II trial showed that 98.5% of pirfenidone-
treated IPF patients had complications including various
adverse effects as compared to that of 88.9% of the placebo
group [9]. Photosensitivity, nausea, anorexia, and fatigue were
observed in 43.8%, 21.9%, 31.5%, and 21.9%, respectively, of the
patients; moreover, a signiﬁcant increase in the frequency of
these side effects was observed in the pirfenidone group than
that of the placebo group. Photosensitivity can be controlled by
prophylactic sunscreen use, which is recommended in the
guideline of Shionogi & Co., Ltd. Gastrointestinal adverse effects
are the most important dose-limiting and withdrawal-
determining factors of pirfenidone.
Thus, if we can predict the responsiveness and adverse
effects of pirfenidone treatment in IPF patients, treatment
regimens could be better managed. In this study, we exam-
ined the predictors of responsiveness and adverse effects of
pirfenidone in IPF patients treated in our institute.cyclosporine (n)
Inhalation of
N-acetyl-cysteine (n)
1
Abbreviations: IQR, interquartile range; CS, current smokers; ES, ex-
smokers; NS, non-smokers; SLB, surgical lung biopsy; MRC scale,
Medical Research Council score for shortness of breath upon
exertion; VC, vital capacity; IPF, idiopathic pulmonary ﬁbrosis;
KL-6, Krebs von den Lungen-6; SP-D, surfactant protein-D.2. Materials and methods
2.1. Subjects
From January 1, 2009 to January 1, 2011, 41 patients with IPF
were prospectively enrolled and treated with pirfenidone(Shionogi & Co., Ltd., Osaka, Japan) in National Hospital Organi-
zation Kinki-Chuo Chest Medical Center (NHO-KCCMC). In-
formed consent was obtained from all subjects. The institutional
review board at NHO-KCCMC approved this study (approval
number: Jutaku-20-22; approval date: January 16, 2009).
Twenty-three patients were clinically diagnosed with IPF with
an usual interstitial pneumonia (UIP) pattern using high-
resolution computed tomography (HRCT), while 18 patients were
histologically diagnosed as IPF/UIP by surgical lung biopsy (SLB)
specimens under the American Thoracic Society (ATS)/European
Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin
American Thoracic Society guidelines for IPF [10]. HRCT patterns
(e.g., UIP pattern or possible UIP pattern) upon pirfenidone
initiation were also evaluated in IPF/UIP cases. The patients'
demographics are summarized in Table 1.
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Pulmonary function tests, including VC, total lung capacity
(TLC), and diffusing capacity of carbon monoxide (DLCO), were
performed using CHESTAC-8800 (Chest M.I., Inc., Tokyo,
Japan). A 6-min walk test was performed in accordance with
ATS guidelines [11]. Serum Krebs von den Lungen-6 (KL-6)
and surfactant protein-D (SP)-D were measured by the
enzyme-linked immunosorbent assay using commercially
available kits [12]. Dyspnea was assessed by the modiﬁed
Medical Research Council (MRC) scale from the ATS/ERS [13].2.3. IPF severity grade
The IPF severity grade was classiﬁed per the JRS criteria [7]
using the arterial oxygen tension (PaO2) at rest and minimum
SpO2 during a 6-min walk test performed before pirfenidone
initiation. Patients with a PaO2Z80 Torr were classiﬁed as
grade I; Z70 Torr and o80 Torr as grade II; Z60 Torr and
o70 Torr as grade III; and o60 Torr as grade IV. For patients
with Zgrade II, if the SpO2 during a 6-min walk test was
o90%, then the severity grade was increased by one grade.2.4. Pirfenidone administration
Pirfenidone daily dosing was increased in a stepwise manner
from 600 to 1800 mg every 2 weeks [7]. The median maximum
dose was 1800 mg (range, 600–1800 mg), and the median ﬁnal
dose in the treatment period was 1200 mg (range, 600–
1800 mg). The dose was decreased in accordance with the
occurrence of adverse events. The median observation period
for each IPF patient administered pirfenidone was 400 days
(range, 12–885 days).2.5. Pirfenidone response
A comprehensive evaluation of the patients was performed
regarding short-term responsiveness at 3–6 months after
pirfenidone initiation to classify the patients as experiencing
either an improvement (good response) or a deterioration of
at least 2 of the 3 parameters (clinical symptoms, radiological
ﬁndings, and physiological ﬁndings) according to modiﬁed
criteria [14] of JRS, as well as King et al. [15] on the basis of a
prior ATS/ERS consensus statement on IPF that was pub-
lished in 2000 [16]. Stable state was deﬁned as neither
improvement nor deterioration. Evaluation of each parameter
is deﬁned in the online supplement (Table S1 in the online
supplementary data).
The effects of pirfenidone in 10 IPF cases could not
be evaluated because of death (n¼1; pirfenidone treatment,
12 days), transfer to other hospitals (n¼1; pirfenidone treat-
ment, 88 days), or pirfenidone withdrawal because of adverse
effects (n¼8; pirfenidone treatment range, 10–65 days) within
3 months of initiation. Thus, short-term responsiveness
was evaluated in 31 cases. One patient who died within
3–6 months of pirfenidone initiation was evaluated as
deteriorated.2.6. Evaluation and treatment of adverse effects, including
anorexia, nausea, or both
Adverse effects in all cases were evaluated using the Com-
mon Terminology Criteria for Adverse Events (v. 4). Acute
exacerbation of IPF was deﬁned according to the criteria in
Japan [7,14]. Of all adverse effects, we evaluated nausea or
anorexia that would be classiﬁed as Zgrade 2. In grade 2,
oral ingestion decreased without signiﬁcant weight loss; in
grade 3, hospitalization was necessary because of signiﬁcant
weight loss secondary to inadequate oral ingestion. Drugs to
protect the gastric mucosa and activate gastric motility, includ-
ing proton pump inhibitors (PPIs) and histamine H2-receptor
antagonists (H2RAs), were administered before IPF treatment
because of comorbidities that included chronic gastritis, gastric/
duodenal ulcers, and gastroesophageal reﬂux disease. The PPIs,
including omeprazole, lansoprazole, and rabeprazole, were
administered to 2, 5, and 9 cases, respectively. Cimetidine
(H2RA) was administered to 3 cases. Each patient was addition-
ally prescribed several types of drugs for gastrointestinal
symptoms if nausea, anorexia, or both occurred.
2.7. Statistical analyses
Patient demographics data are presented as frequency (%) or
median with a range. Correlation between pirfenidone response
and IPF severity grade was examined by Fisher's exact test and
Spearman rank correlation. Univariate and multivariate logistic
regression analyses were performed to clarify the predictors of
pirfenidone responsiveness. Each numerical parameter was
divided into 2 groups by the median. For grades Z2, the
Kaplan–Meier method was used to assess the occurrence of
nausea, anorexia, or both as adverse effects according to time
without nausea/anorexia for IPF patients taking pirfenidone.
Clinical parameters determining the occurrence of anorexia,
nausea, or both were examined by univariate and multivariate
Cox proportional hazard regression analyses. A P-value ofo0.05
was considered statistically signiﬁcant. All statistical analyses
were performed using SPSS software (v.19) (Chicago, IL, USA).3. Results
3.1. Short-term pirfenidone response and IPF severity
stage
Physiological and radiological improvements were observed in
4 cases and 2 cases, respectively. Symptoms improved in 11
cases (cough, 8 cases; shortness of breath, 6 cases). A compre-
hensive assessment revealed that 6 cases improved 3–6 months
after pirfenidone initiation. The patients' pirfenidone response
was found to be signiﬁcantly associated with the IPF severity
grade using the Fisher's exact test (P¼0.025) and Spearman
rank correlation (ρ¼0.5039; P¼0.0039) (Table 2).
3.2. Predictors of short-term pirfenidone response
Using the 2 signiﬁcant parameters as determined by the
univariate analysis (Table S2 in the online supplementary data),
the multivariate analyses (Table 3) showed that diagnosis with
Table 2 – Short-term response to pirfenidone.
Severity grade of IPF
I II III IV
n 8 3 8 12
VC, %predicted (IQR) (%) 76.6 (69.7–83.2) 87.6 (86.0–88.9) 64.8 (57.7–71.7) 58.9 (47.7–64.5)
Response to pirfenidone
Improvement (n) 3 2 1 0
Stable (n) 5 1 3 7
Deterioration (n) 0 0 4 5
Abbreviations: IPF, idiopathic pulmonary ﬁbrosis; VC, vital capacity; IQR, interquartile range. Signiﬁcant correlation between response to
pirfenidone and severity grade of IPF was observed by Fisher's exact test (p¼0.025). Deﬁnition of severity grade and response of pirfenidone
was described in Section 2 and Table S1 in the online supplementary data.
Table 3 – Predictors of short-term good response to
pirfenidonea.
Factors Odds ratio 95% CI p-value
Severity grade (I/II) 32.988 1.813–600.319 0.018
Diagnosis (SLB) 23.651 1.265–442.125 0.034
Abbreviations: CI, conﬁdence interval; SLB, surgical lung biopsy; IPF,
idiopathic pulmonary ﬁbrosis.
a Univariate logistic regression analysis was performed using age
(r70 years), smoking status (non-smoker), diagnosis by SLB,
severity grade (I/II), Modiﬁed Medical Research Council scale for
shortness of breath upon exertion (0–1), cholinesterase (4270 U/L),
Krebs von den Lungen-6 (4858 U/mL), surfactant protein-D
(4187 ng/mL) and usage of proton pump inhibitor (Table S2 in
the online supplementary data). Multivariate logistic regression
analysis was performed using signiﬁcant parameters by univariate
analysis (e.g. diagnosis with SLB and severity grade of IPF) (Table S2).
Fig. 1 – A change in vital capacity (VC; L/year) was compared
with the Wilcoxon signed-rank test between 3 and 12
months before and 3 and 6 months after pirfenidone
initiation with (A) severity grade I/II (n¼10) and (B) severity
grade III/IV (n¼11). In severity grade I/II patients, the change
in VC signiﬁcantly decreased after pirfenidone initiation
(p¼0.0039) (A). However, the change in VC did not
signiﬁcantly decline in severity grade III/IV patients
(p¼0.1748) (B). The change in VC before pirfenidone
administration in severity grade I/II patients was
signiﬁcantly smaller than that of severity grade III/IV
patients with Wilcoxon rank-sum test (p¼0.0290).
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severity grade of I/II. Similar results were found in the evaluable
short-term response cases after the addition of 1 deceased
case that had died 12 days after pirfenidone initiation. No
difference was observed between clinical IPF and IPF/UIP at
pirfenidone initiation, except for age, gender, and HRCT pat-
terns (Table S3 in the online supplementary data).
3.3. VC change before and after pirfenidone initiation
A change (L/year) in VC could be compared between 3 and 12
months before and 3 and 6 months after pirfenidone initiation
by the Wilcoxon signed-rank test in 21 cases. In patients with
severity grade I/II, the change in VC signiﬁcantly decreased after
pirfenidone initiation (n¼10; P¼0.0039) (Fig. 1A). However, the
VC change did not signiﬁcantly decline in IPF patients with
severity grade III/IV (n¼11; P¼0.1748) (Fig. 1B). Patients with
severity grade I/II experienced a VC change before pirfenidone
administration that was signiﬁcantly smaller than that of
patients with severity grade III/IV using the Wilcoxon rank-
sum test (P¼0.0290).
3.4. Pirfenidone adverse effects
Adverse effects were observed in 31 of the 41 IPF patients (75.6%)
following pirfenidone initiation. Anorexia, nausea, or both wereobserved in 24 of the 41 (58.5%) IPF patients. Other adverse
effects were photosensitivity (5 cases, 12.2%), allergic skin reac-
tion (2 cases, 4.9%), sleepiness (2 cases, 4.9%), photophobia (1
case, 2.4%), vertigo (1 case, 2.4%), diarrhea (1 case, 2.4%), and
acute exacerbation (4 cases, 9.8%). Pirfenidone was ceased in 15
cases (34.1%) because of anorexia, nausea, or both (6 cases,
14.6%); disease progression including acute exacerbation (7 cases,
17.1%); and transfer to other hospitals (2 cases, 4.9%). Six cases
(14.6%) died from disease progression.
3.5. Pirfenidone induced anorexia, nausea, or both
Nineteen IPF cases (acid-secretion inhibitor group) were taking
PPIs or H2RAs before pirfenidone initiation as treatment for
Table 4 – Prophylactic effects of acid-secretion inhibitors on anorexia and/or nausea due to pirfenidone.
Drugs at the introduction of pirfenidone No. of cases Anorexia and/or nausea Dose reduction of pirfenidone
None Reduction Withdrawal
Acid-secretion inhibitorsa (n) 19 8 3 4 1
No acid-secretion inhibitorsb (n) 22 16 7c 4 5
Frequency of anorexia and/or nausea was signiﬁcantly less in the acid-secretion inhibitors group than that in the no acid-secretion inhibitors
group as determined by the chi-square test (po0.05).
a Proton pump inhibitors (PPIs) or histamine H2-receptor antagonists (H2RA) were administered. The PPIs, omeprazole, lansoprazole, and
rabeprazole, were administered to two, ﬁve, and nine cases, respectively. The H2RA, cimetidine, was administered in three cases.
b Acid-secretion inhibitors were not administered, but drugs for gastritis, drugs to protect gastric mucosa or to activate motility of the gastro-
intestinal tract were administered. Gastrointestinal drugs in detail were shown in Table S4 in the online supplementary data.
c Anorexia and/or nausea improved after the additional use of PPIs after the onset of the adverse effects.
Fig. 2 – Kaplan–Meier plots of anorexia/nausea-free time in IPF
patients administered pirfenidone and acid-secretion
inhibitors (solid line) or pirfenidone alone (dotted line). The
median anorexia/nausea-free time from pirfenidone initiation
to the onset of anorexia/nausea in patients with Zgrade 2
was signiﬁcantly shorter in cases with no acid-secretion
inhibitors (34 days) than in cases with acid-secretion inhibitors
(324 days), as determined by log-rank test (p¼0.0211). Cases
that continued pirfenidone treatment and then stopped
because of other adverse events, other than anorexia, nausea,
or both, were treated as censored cases.
Table 5 – Predictors of nausea and/or anorexia caused by
pirfenidone♯.
Factors Risk ratio 95% CI p-value
Acid-secretion
inhibitors (Noa)
2.346 1.053–5.591 0.037
Age (470 years) 1.910 0.868–4.410 0.1083
Abbreviations: PPI, proton pump inhibitor; CI, conﬁdence interval.
♯ Multivariate Cox proportional Hazard analysis was performed
using two parameters with p-value less than 0.10 by univariate
Cox proportional Hazard analysis using age (470 years), smoking
status (non-smoker), diagnosis (clinical), severity grade (IV),
Modiﬁed Medical Research Council scale for shortness of breath
upon exertion (0–2), serum cholinesterase (4270 U/L), no
administration of acid-secretion inhibitors and administration
of prednisolone described in Table S5 in the online
supplementary data.
a PPIs and histamine H2-receptor antagonists was not adminis-
tered at the commencement of pirfenidone.
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 1 3 6 – 1 4 3140other comorbidities (Table 4). The other 22 cases (no acid-
secretion inhibitor group) were not administered acid-secretion
inhibitors but administered drugs to protect the gastric mucosa.
No signiﬁcant difference in frequency of coadministered gastro-
intestinal drugs was observed between the 2 groups (Table S4 in
the online supplementary data). One case was administered
drugs to activate gastrointestinal motility. There was no differ-
ence in pirfenidone dose between the 2 groups.
In the no acid-secretion inhibitor group, 16 cases (72.7%)
complained of anorexia, nausea, or both, and 5 cases (22.7%)
ceased taking pirfenidone; however, 7 cases continued to take
pirfenidone because of additional PPI usage. In the acid-
secretion inhibitor group, anorexia, nausea, or both occurred
in only 8 cases (42.1%), and almost all cases remained on
pirfenidone but with a dose reduction (Table 4). The χ2 tests
revealed that anorexia, nausea, or both occurred at a signiﬁ-
cantly lower frequency in the acid-secretion inhibitor group
(Po0.05). The anorexia-free time (median, days) in the IPFpatients administered pirfenidone in the acid-secretion inhibi-
tor group was 324 days (Kaplan–Meier method), and this was
signiﬁcantly longer than that of the no acid-secretion inhibitor
group (34 days) (Fig. 2).
3.6. Predictors of anorexia, nausea, or both with
pirfenidone administration
A univariate analysis (Table S5 in the online supplementary
data) using the Cox proportional hazard regression analyses
revealed that the lack of acid-secretion inhibitors was the
only signiﬁcant factor. Prednisolone administration did not
affect the onset of nausea, anorexia, or both. The multivariate
analyses using factors with a P-value of o0.10 (Table 5)
showed that the lack of acid-secretion inhibitors was a
signiﬁcant predictor of anorexia, nausea, or both.4. Discussion
Our investigation demonstrated that the IPF severity grade (I/II)
was a signiﬁcant predictor of a short-term, good response to
pirfenidone. Azuma et al. [17] performed an exploratory analysis
in a phase III pirfenidone trial and reported that pirfenidone was
effective in IPF patients with a %VC Z70% or PaO2 Z70 Torr and
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to that of the placebo group. Their criteria for good responders
corresponded to IPF cases with mild-to-moderate lung function
impairment, although it was not necessarily similar to stage I/II
per the JRS criteria. IPF cases with severity grade I/II also had a
signiﬁcant decrease in VC change after pirfenidone initiation.
Thus, pirfenidone might have some effects in the unimproved
grade I/II cases.
Another important predictor of a good response to pirfe-
nidone was diagnosis by SLB specimens. Five of the 6 IPF
cases with a good, short-term response to pirfenidone were
diagnosed by an SLB. Similar results were reported in a
bosentan clinical trial for IPF [18]. These results might be
explained by the hypothesis that the beneﬁcial effect was
greater in IPF cases with a possible UIP pattern on HRCT. It is
true that all the IPF/UIP cases in our study demonstrated a
possible UIP pattern at diagnosis; however, the HRCT pattern
in 8 of the 13 IPF/UIP cases was a deﬁnite UIP pattern upon
pirfenidone initiation, and 3 of the 5 IPF/UIP cases that had a
good response to pirfenidone exhibited a deﬁnite UIP pattern.
Thus, other factors supposedly have an effect on a good
response, although the HRCT pattern might be partially
associated with a good response. A detailed reevaluation of
the pathological and radiological ﬁndings may be warranted
to determine the features associated with a good response to
pirfenidone.
We performed a multidisciplinary evaluation of a pirfeni-
done response using radiological and symptomatic para-
meters, in addition to physiological parameters. Iwashita
et al. reported that the radiological ﬁndings have improved
in only 3 of the 38 cases 1 year after pirfenidone initiation
[19], which is consistent to our result. However, our investi-
gation showed that radiologic improvement could be
observed in shorter treatment periods, 3–6 months after
pirfenidone initiation. The degree of cough had not been
evaluated in previous reports. We observed a cough improve-
ment in some cases, although it remains unclear if this was
because of a direct effect of pirfenidone. Acute exacerbation
of IPF was not inhibited by pirfenidone in the phase III trials
[7]. However, the incidence of acute exacerbation in our
population (9.8%) was high, as compared with that of the
previous clinical trials [7,9]. This may have occurred because
severe cases were included in this study.
Taniguchi et al. reported that the short-term effects could
predict the long-term effects of pirfenidone, using data from a
Japanese phase III clinical trial [20]. They evaluated pirfenidone-
treated IPF patients for 3 months and categorized them into 2
groups: a “worsening” group with a relative VC decline of Z5%
and a “no worsening” group with no such decline. For 71.7% of
the pirfenidone-treated cases in the “no worsening” group, no
deterioration occurred 1 year posttreatment, while 87.1% of the
pirfenidone-treated cases in the “worsening” group deteriorated
1 year posttreatment. In our examination, 5 of the 6 short-term
improvement cases remained on pirfenidone for 41 year, and
4 of the 5 cases were evaluated as stable (data not shown).
Although our investigation of the long-term effects was not
sufﬁcient, evaluation of the short-term effects may be useful for
predicting long-term responsiveness.
Pirfenidone is a promising drug for IPF; however, adverse
effects (photosensitivity and anorexia and/or nausea)frequently occurred in several clinical trials [5–7,9]. Gastro-
intestinal adverse effects are the most important dose-
limiting and withdrawal-determining factors of pirfenidone.
Our investigation showed the possible preventive effects of
PPIs and H2RA against nausea, anorexia, or both.
The pathophysiology of anorexia and nausea with pirfe-
nidone administration has not been fully elucidated; how-
ever, it might be associated with the suppression of gas-
trointestinal motility [21]. Although gastroscopy was not
performed on any of our cases, we do not believe anorexia
occurred from gastroduodenal ulcers, as it spontaneously
resolved after pirfenidone discontinuation. PPIs and H2RAs
do not directly activate gastric motility; however, they are
known to improve postprandial fullness and early satiation
observed in functional dyspepsia without organic disease [22]
through attenuating duodenal hypersensitivity to acids [23].
It is reported that PPI monotherapy improves dysmotility-like
symptoms signiﬁcantly better than that of H2RAs plus mosa-
pride in functional dyspepsia [24].
The effect of PPIs on the pharmacokinetics of pirfenidone
is an important problem. Although neutralizing acid does not
affect pirfenidone absorption or its plasma concentration [25],
drug interactions between PPIs and pirfenidone should be
considered. In vitrometabolism studies revealed that approxi-
mately 48% of pirfenidone is metabolized via cytochrome
P450 (CYP) 1A2, while o13% is done so by each of CYP2C9,
2C19, 2D6, and 2E1 [26]. PPIs inhibit some CYP reactions;
however, all the CYPs associated with pirfenidone metabo-
lism are not simultaneously inhibited [27], and we postulate
that the inhibitory effects of pirfenidone may be clinically
limited.
In vitro evaluations using hepatoma cell-lines showed that
CYP1A2, the most important metabolizer of pirfenidone, was
induced by omeprazole and lansoprazole, but not by rabe-
prazole [28]. Thus, omeprazole and lansoprazole may accel-
erate pirfenidone metabolism and theoretically decrease its
serum concentration and clinical effects; however, in vitro
studies are not always consistent with in vivo studies. In vivo
interactions of theophylline and caffeine, which are metabo-
lized by CYP1A2, with omeprazole could be clinically negli-
gible in accordance to pharmacokinetic studies [29]. Although
the coadministration of pirfenidone and PPIs might not affect
the in vivo clinical effects, rabeprazole is better than omepra-
zole and lansoprazole from the standpoint of CYP1A2 induc-
tion. Rabeprazole was administered to 2 of the 6 improved
cases in our examination (data not shown). Esomeprazole
may be another important PPI, as it does not interact with
drugs metabolized by CYP1A2 [30].
As for H2RAs, cimetidine is known to interfere with the
metabolism of many drugs by inhibiting CYP3A4, CYP1A2,
and CYP2D6 [31]. Thus, cimetidine and pirfenidone coadmi-
nistration might lead to elevated serum pirfenidone levels
and deteriorating gastrointestinal symptoms in some cases.
Interactions of ranitidine and famotidine with CYP isoen-
zymes are weak and negligible [32,33].
Our study had several limitations. First, this was not a
randomized trial, and PPIs were used for comorbidities.
Second, the number of patients was small. Future rando-
mized, controlled trials are necessary to assess the effects of
PPIs on nausea, anorexia, or both caused by pirfenidone.
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 1 3 6 – 1 4 31425. Conclusion
IPF patients with a mild disease, diagnosis by SLB, or both
showed indications of a good response to pirfenidone. In
addition, acid-secretion inhibitors may reduce the frequency
of nausea, anorexia, or both from pirfenidone.Conﬂict of interest
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